Konakion Novum (Phytomenadione)

Phytomenadione, the active ingredient in Konakion Novum, is a vitamin K hemostatic agent presented as an injectable preparation for intramuscular, intravenous, and oral use. It restores normal coagulation in patients with vitamin K deficiency, counteracts bleeding associated with anticoagulant therapy, and provides neonatal prophylaxis against hemorrhagic disease.

GNH USA supplies Konakion Novum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across all markets through rigorous manufacturing standards and validated distribution processes.

Konakion Novum, a vitamin K hemostatic agent, is used to manage disorders of coagulation related to vitamin K deficiency. - Vitamin K deficiency: restores clotting factor activity to correct bleeding tendencies. - Anticoagulant‑associated bleeding: reverses the effects of warfarin and other vitamin K antagonists to stop hemorrhage. - Neonatal hemorrhagic disease prophylaxis: prevents bleeding in newborns at risk of vitamin K deficiency. - Pre‑operative preparation: ensures adequate clotting status before surgical procedures in patients with low vitamin K levels.

Phytomenadione may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain: mild discomfort or tenderness at the site of administration. - Erythema: redness of the skin around the injection area. - Nausea: transient feeling of queasiness. - Headache: mild to moderate headache.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with difficulty breathing, swelling, and hypotension. - Hemolysis: destruction of red blood cells leading to anemia. - Thrombosis: formation of abnormal clots in blood vessels. - Elevated liver enzymes: signs of hepatic stress or injury.

When using Konakion Novum, several precautions should be observed to ensure safe administration. - Allergy assessment: verify no known hypersensitivity to phytomenadione or excipients. - Bleeding disorders: monitor coagulation parameters in patients with existing clotting abnormalities. - Concurrent anticoagulants: adjust dosing and observe for over‑correction of anticoagulation. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Neonatal use: follow established dosing guidelines and monitor bilirubin levels. - Store at ambient temperature: keep below 25 °C, protect from moisture and light, retain in original packaging.

Phytomenadione can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Warfarin and other vitamin K antagonists: concurrent use may diminish anticoagulant effect, requiring close monitoring. - Broad‑spectrum antibiotics (e.g., cephalosporins): may reduce vitamin K synthesis, increasing need for phytomenadione. - High‑dose vitamin K supplements: may counteract therapeutic action.

Moderate Interactions (Monitor Closely): - Heparin: combined anticoagulant therapy may increase bleeding risk. - Oral contraceptives: may alter vitamin K metabolism, necessitating observation. - Lipid‑lowering agents (statins): potential effect on vitamin K‑dependent pathways.